ArticleInternational journal of women's health2026
The Association of Methylenetetrahydrofolate Reductase C677T Polymorphism, Serum 5-Methyltetrahydrofolate, and Homocysteine Levels with Adenomyosis: A Cross-Sectional Study in an Indonesian Population.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Adenomyosis is a complex uterine condition, with emerging evidence indicating epigenetic alterations play a role in its pathogenesis. The methylenetetrahydrofolate reductase (MTHFR) gene polymorphism C677T may reduce enzyme activity, affecting DNA methylation and increasing adenomyosis risk. This study compares the MTHFR C677T polymorphism, 5-methyltetrahydrofolate (5-MTHF) levels, and homocysteine levels in patients with adenomyosis. Patients and Methods: This cross-sectional study involved 61 subjects: 31 patients with adenomyosis and 30 patients as controls. The MTHFR C677T polymorphism was analyzed using PCR-RFLP, serum 5-MTHF and homocysteine levels were measured using ELISA. Statistical analyses were performed to compare genotype distributions and metabolite levels between groups and within the adenomyosis group based on genotype. Results: The study found a significant difference in the distribution of the MTHFR C677T genotype between adenomyosis and control groups (p=0.018), with a higher prevalence of the CT genotype in the adenomyosis group (35.5% vs 10.0%). The frequency of the T allele was also elevated in the adenomyosis group (17.7% vs 5.0%; p=0.027). Serum 5-MTHF levels were notably lower in the adenomyosis group (23.92 ± 4.599 nmol/l) compared to controls (32.45 ± 3.019 nmol/l; p<0.0001), while homocysteine levels were significantly higher in the adenomyosis group (12.87 ± 8.916 µmol/L vs 8.61 ± 1.352 µmol/L; p=0.019). Further analysis of MTHFR genotypes indicated lower 5-MTHF levels in both CC and CT genotypes among the adenomyosis group compared to controls (p<0.0001). Homocysteine levels showed no significant difference across genotypes (p=0.074), though there was a trend towards higher levels in the adenomyosis group. Conclusion: This study demonstrates a significant difference in the distribution of the MTHFR C677T polymorphism, lower 5-MTHF levels, and higher homocysteine levels in patients with adenomyosis compared to controls. Lower 5-MTHF levels were also shown to be strongly linked with the heterozygous C677T polymorphism in the adenomyosis group.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.